Streetbeat News

Corporate Responsibility

XPON

Expion360 announced that its EX1 SmartTalk Bluetooth Batteries have achieved UL 1973 compliance, underscoring the company's dedication to safety and innovation within the expanding lithium battery market. The UL 1973 compliant batteries are now being shipped to customers.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 12:32 pm

PXMD

PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company, announced the release of its latest company presentation, highlighting its advancements in Autism Spectrum Disorder (ASD) treatments. The presentation showcases PaxMedica's strategic direction, its leading investigational drug PAX-101, and its commitment to addressing unmet needs within the ASD community. The company aims to transform the treatment landscape for ASD, offering hope to affected individuals and their families.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 12:22 pm

AER

AerCap Holdings N.V. (AER) has delivered the first of four Airbus A330neo aircraft to Corsair, with the remaining three scheduled for delivery through 2024. This delivery marks the beginning of the final phase of Corsair's fleet renewal plan, aiming to modernize and enhance sustainability by reducing emissions and improving operational efficiency. By the end of 2024, Corsair plans to operate all routes with A330neo aircraft, making its fleet one of the youngest and most environmentally friendly in the world.

Portfolio Pulse from Happy Mohamed

March 13, 2024 | 12:11 pm

BGNE

The Max Foundation, BeiGene, and the BeiGene Foundation have initiated the distribution of BRUKINSA, a treatment for Chronic Lymphocytic Leukemia, to patients in low- and middle-income countries, starting with Armenia and Nepal. This effort is part of a collaboration aimed at improving access to this critical medication in 29 countries.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 12:08 pm

CPRX

Catalyst Pharmaceuticals announced the U.S. commercial launch of AGAMREE for Duchenne Muscular Dystrophy (DMD) treatment in patients aged two and older. AGAMREE, approved by the FDA on October 26, 2023, is now available by prescription. It offers a novel alternative to current steroid treatments, potentially reducing side effects and improving quality of life for DMD patients. Catalyst's Pathways Program supports patient access and education. AGAMREE has shown comparable efficacy to standard corticosteroids with a better side effect profile in clinical trials.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 12:01 pm

GOOGL

Google has implemented restrictions on its AI chatbot, Gemini, to limit responses to election-related queries, aiming to prevent misinformation. This move is part of Google's election integrity strategy, especially relevant as India approaches its elections. The restrictions are already in effect in India, where Gemini directs users to Google Search for questions about elections in the U.S., U.K., and South Africa, but still answers queries on Indian politics. This decision aligns with global concerns over AI's role in spreading election misinformation and follows regulatory actions in India requiring tech companies to seek approval before deploying certain AI tools.

Portfolio Pulse from Benzinga Neuro

March 13, 2024 | 12:01 pm

AGRX

Agile Therapeutics has fully repaid its debt facility with Perceptive Advisors, focusing on expanding Twirla and advancing its business plan.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 11:42 am

ARCO

Arcos Dorados announced plans to open 80 to 90 new restaurants in 2024, with approximately 90% being free-standing units. The company anticipates total capital expenditures for 2024 to be between $300M and $350M.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 11:36 am

HSBC

HSBC has announced the appointment of Andrew Fullam as the new Chief Financial Officer (CFO) for the US and Americas. This strategic move aims to strengthen HSBC's financial leadership and operational efficiency in these key markets.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 11:32 am

TSLA

Tesla shareholders, upset with the Delaware Court's nullification of CEO Elon Musk's 2018 compensation package worth $56 billion, attempted to influence the court through letters and are now considering a floral tribute to shareholder rights. The court's decision, seen as unfair by some shareholders, led to a unique form of protest supported by Musk himself.

Portfolio Pulse from Anan Ashraf

March 13, 2024 | 11:27 am